Date: 2013-03-07
Type of information: R&D agreement
Compound: drugs targeting cancer metabolism
Company: AstraZeneca (UK) Cancer Research Technology (CRT) (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: CRT, Cancer Research UK’s commercialisation company, and AstraZeneca have extended their multi-project cancer metabolism alliance for a further two years. The three-year alliance, aiming to develop a drugs pipeline targeting cancer metabolism, has been expanded to run to early 2015 - adding two further years for development of the existing portfolio of four projects and the possibility of at least two new projects being selected by CRT from Cancer Research UK’s research in cancer metabolism. The alliance team will continue to work at CRT’s Discovery Laboratories in London and Cambridge, and AstraZeneca’s cancer research centre, Alderley Park, Manchester.
Financial terms:
Latest news:
